Highlights
- •A total of 18.6% of surgically treated adult spinal deformity patients indicated they were unsure or would not undergo surgery again.
- •Patients indicating they were unsure or wound not have surgery again had more postoperative complications requiring surgery than patients indicating they would have surgery again.
- •Patients indicating they were unsure or wound not have surgery again had worse postoperative PROs and fewer percentages reaching minimal clinically important difference for SRS-22r and ODI than patients indicating they would have surgery again.
- •At minimum 2 year follow-up 93.0% of patients indicating they would have surgery again reported they were satisfied with the results of their back management compared 82.3% of unsure if they would have the same surgery again and 72.4% of patients that wound not have surgery again (p<.05).
- •Surgeons accurately identified patients indicating they would have surgery again (91.1%) but poorly identified patients indicating they wound not have surgery again (13.8%; p<.05).
Abstract
BACKGROUND
PURPOSE
STUDY DESIGN
PATIENT SAMPLE
OUTCOME MEASURES
METHODS
RESULTS
CONCLUSIONS
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Spine JournalReferences
- The health impact of symptomatic adult spinal deformity: comparison of deformity types to United States population norms and chronic diseases.Spine (Phila Pa 1976). 2016; 41: 224-233
- Operative versus nonoperative treatment for adult symptomatic lumbar scoliosis.J Bone Joint Surg Am. 2019; 101: 338-352
- Counseling guidelines for anticipated postsurgical improvements in pain, function, mental health, and self-image for different types of adult spinal deformity.Spine (Phila Pa 1976). 2020; 45: 1118-1127
- A comparison of patient and surgeon expectations of spine surgical outcomes.Global Spine J. 2021; 11: 331-337
- Prediction of satisfaction after correction surgery for adult spinal deformity: differences between younger and older patients.Eur Spine J. 2020; 29: 3051-3062
- The patient generated index and decision regret in adolescent idiopathic scoliosis.Spine Deform. 2020; 8: 1231-1238
- Why are patients dissatisfied after spine surgery when improvements in disability and pain are clinically meaningful?.Spine J. 2020; 20: 1535-1543
- Importance of patient-reported individualized goals when assessing outcomes for adult spinal deformity (ASD): initial experience with a patient generated index (PGI).Spine J. 2017; 17: 1397-1405
- Concordance between patients' and surgeons' expectations of lumbar surgery.Spine (Phila Pa 1976). 2021; 46: 249-258
- SRS-22R minimum clinically important difference and substantial clinical benefit after adult lumbar scoliosis surgery.Spine Deform. 2018; 6: 79-83
- The minimum clinically important difference in Scoliosis Research Society-22 Appearance, Activity, And Pain domains after surgical correction of adolescent idiopathic scoliosis.Spine. 2010; 35: 2079-2083
- Minimum clinically important difference in lumbar spine surgery patients: a choice of methods using the Oswestry Disability Index, Medical Outcomes Study questionnaire Short Form 36, and pain scales.Spine J. 2008; 8: 968-974
- [Validation of a tool to measure pelvic and spinal parameters of sagittal balance].Revue de chirurgie orthopedique et reparatrice de l'appareil moteur. 2003; 89: 218-227
- Center of gravity and radiographic posture analysis: a preliminary review of adult volunteers and adult patients affected by scoliosis.Spine (Phila Pa 1976). 2005; 30: 1535-1540
- A comparison of a modified Oswestry Low Back Pain Disability Questionnaire and the Quebec Back Pain Disability Scale.Phys Ther. 2001; 81: 776-788
- The Oswestry low back pain disability questionnaire.Physiotherapy. 1980; 66: 271-273
- User’s manual for the SF-36v2 health survey.2nd ed. QualityMetric Incorporated, London2007
- SF-36 health survey update.Spine. 2000; 25: 3130-3139
- Predictors of patient dissatisfaction at 1 and 2 years after lumbar surgery.J Neurosurg Spine. 2019; 32: 1-10
- Discrepancies between patient and surgeon expectations of surgery for sciatica: a challenge for informed decision making?.Spine (Phila Pa 1976). 2019; 44: 740-746
- Factors associated with patient satisfaction in surgery: the role of patients' perceptions of received care, visit characteristics, and demographic variables.J Surg Res. 2010; 164: e53-e59
- Are preoperative health-related quality of life scores predictive of clinical outcomes after lumbar fusion?.Spine. 2009; 34: 725-730
- Depression symptoms are associated with poor functional status among operative spinal deformity patients.Spine (Phila Pa 1976). 2021; 46: 447-456
- Preoperative opioid use negatively affects patient-reported outcomes after primary total hip arthroplasty.J Am Acad Orthop Surg. 2019; 27: e1016-e1e20
- Preoperative opioid use is independently associated with increased costs and worse outcomes after major abdominal surgery.Ann Surg. 2017; 265: 695-701
- Preoperative opioid use is associated with worse patient outcomes after Total joint arthroplasty: a systematic review and meta-analysis.BMC Musculoskelet Disord. 2019; 20: 234
- Preoperative chronic opioid therapy: a risk factor for complications, readmission, continued opioid use and increased costs after one- and two-level posterior lumbar fusion.Spine (Phila Pa 1976). 2018; 43: 1331-1338
- Prospective multicenter assessment of perioperative and minimum 2-year postoperative complication rates associated with adult spinal deformity surgery.J Neurosurg Spine. 2016; 25: 1-14
- Effect of serious adverse events on health-related quality of life measures following surgery for adult symptomatic lumbar scoliosis.Spine (Phila Pa 1976). 2019; 44: 1211-1219
Article info
Publication history
Publication stage
In Press Journal Pre-ProofFootnotes
FDA device/drug status: Not applicable.
Author disclosures: SB: Grant: depuy synthes (F, Paid directly to institution), nuvasive (F, Paid directly to institution), k2m stryker (F, Paid directly to institution), issgf (E, Paid directly to institution); Royalties: k2m stryker (F), nuvasive (C); Consulting: stryker (C), mirus (B), atec (D); Speaking and/or Teaching Arrangements: stryker (B), atec (B); Grant: Medtronic (F, Paid directly to institution), depuy synthes (F, Paid directly to institution), nuvasive (F, Paid directly to institution), globus (E, Paid directly to institution), Carlsmed (E, Paid directly to institution), sea spine (E, Paid directly to institution), stryker (F, Paid directly to institution). BL: Consulting: Internation Spine Study Group Foundation (D), CA: Nothing to disclose. DB: Royalties: DePuy Spine (B), Globus, Blue Ocean; Stock Ownership: Progenerative Medical (B), Consulting: Blue Ocean Spine (none to date), DePuy Spine (A), Globus (B); Board of Directors: Scoliosis Research Society, International Spine Study Group; Reserch Support (Investigator Salary, Staff/Materials): DePuy Spine (E, Paid directly to institution), Pfizer (B, Paid directly to institution), Bioventus (B, Paid directly to institution). GM: Royalties: Nuvasive (E), Seaspine, Stryker (C); Stock Ownership, Seaspine (B), Consulting: Nuvasive (F), Seaspine (D), Viseon (B), SI BONE (C), Board of Directors: Globus spine outreach, San Diego Spine Foundation; Scientific Advisory Board/Other Office: Seaspine (C), Nuvasive (C); Fellowship Support: Nuvasive (E), Seaspine (E). RE: Royalties: Globus (B), SI BONE (B), Seaspine (C), Nuvasive (D); Stock Ownership: Carevature (A); Private Investments: Alphatec (Unknown number of options, <1% ownership), Seaspine (Unknown number of options, <1% ownership), SI BONE (Unknown number of options, <1% ownership), Nuvasive (Unknown number of options, <1% ownership); Consulting: Nuvasive (E), Seaspine (C), SI BONE (D), Medtronic (B), Carevature (B), Johnson/Johnson (B), Spine Elements (B), Neo Spine, Silony; Speaking and/or Teaching Arrangements: Radius (A); Board of Directors: San Diego Spine Foundation, Matrisys, Nocimed; Reserch Support (Investigator Salary, Staff/Materials): Medtronic (D, Paid directly to institution), Nuvasive (D, Paid directly to institution), Seaspine (D, Paid directly to institution); Fellowship Support: Nuvasive (F, Paid directly to institution), Seaspine (E, Paid directly to institution), AO, (E, Paid directly to institution). RH: Royalties: DePuy (E), Globus, Seaspine; Consulting: DePuy, Globus (C), Medtronic (C), Allosource (A), Seaspine (C), PropioVision (B), Orthofix; Speaking and/or Teaching Arrangements: DePuy, Globus; Reserch Support (Investigator Salary, Staff/Materials): DePuy, Misonix; MG: Innomed (C), DePuy (G); Stock Ownership: J&J (100 Share); Consulting: Medtronic (C), DePuy (E), Globus (B); Speaking and/or Teaching Arrangements: LSU Grand Round (B), Wright State (A), AO Spine (B); Trips/Travels: Scoliosis Research Society (co-chair course), DePuy (chair course), AO Spine (chair course); Board of Directors: Scoliosis Research Society (nonfinancial); Fellowship Support: AO Spine;Omega (varies year to year). EK: Consulting: DePuy Synthes (F), Stryker (F), Medicrea Medtronic (C), Speaking and/or Teaching Arrangements: AO Spine (B); Board of Directors: AO Spine Incoming Chair, Also Fellow Chair; Fellowship Support: Fellowship Grant. HK: Grant: ISSGF (Variable); Royalties: Zimmerbiomet (F), K2M Stryker (E), Acuity Surgical (B); Consulting: Nuvasive (B); Scientific Advisory Board/ Other Office, Vivex Biology (A), Aspen Medical (B); Fellowship Support: AO Spine (E). RH: Nothing to disclose. KK: Nothing to disclose. VL: Royalties: Nuvasive (C); Stock Ownership: Nemaris Inc (20%), VFT Solution LLC (50%), See spine LLC (33%); Consulting: Globus Medical (B); Alphatec (C); Speaking and/or Teaching Arrangements: Implanet (B), J&J (B), Stryker (C); Scientific Advisory Board/Other Office: ISSG; RL: Nothing to disclose. FS: Royalties: Medtronic (F), Zimmer Biomet (F), Medicrea (B), Stock Ownership: See spine (not compensated), VFT Solutions (not compensated); Consulting: Medtronic (B), Main Stray (C), Grants: DePuy, MDS, Sl Bone, K2M, Stryker (grants paid through ISSGF). CS: ISSG Foundation (D), Royalties: NuVasive (E), Medtronic (D), Sl Bone (C); Stock Ownership: NuVasive (E); Consulting: Medtronic (C), NuVasive (B); Board of Directors: SRS; Scientific Advisory Board/Other Office: Proprio; Grants: NuVasive (B); Fellowship Support: NuVasive (E, Paid directly to institution), Globus (E, Paid directly to institution). JSS: Nothing to disclose. ISSG: Grant: NuVasive (G, Paid directly to institution), K2M/Stryker (F, Paid directly to institution), NuVasive (H, Paid directly to institution), Medtronic, (G, Paid directly to institution), Globus (F, Paid directly to institution), Sl Bone, (E, Paid directly to institution), Stryker (F, Paid directly to institution), DePuy Synthes Spine (G, Paid directly to institution).
Level of evidence: I-IV: Level III; prognostic.
